Maintenance therapy trial for non-HRD ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new maintenance treatment (Mo-Rez) for people with advanced ovarian cancer whose tumors do not have a specific DNA repair problem (HRD). It is for those who have finished first-line platinum chemotherapy and had a good response. The goal is to see if Mo-Rez can help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and legally able to consent.
- You must have newly diagnosed stage 3 or 4 ovarian, primary peritoneal, or fallopian tube cancer of certain types (like high-grade serous or clear cell).
- You must have completed your first round of platinum-based chemotherapy and had a good response (complete or partial response, no evidence of disease, or stable disease).
- You must be able to start the study treatment within 9 weeks of your last chemotherapy dose.
- You must not have a BRCA gene mutation or evidence of HRD (homologous recombination deficiency).
- You must have adequate organ function (liver, kidney, heart) and be in good enough health to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.